Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy

Cancer Science

Volumn 99, Issue 2, 2008, Pages 253-259

  Saito, Kana ^a   Sakurai, Shinji ^a   Sano, Takaaki ^a   Sakamoto, Kazuha ^a   Asao, Takayuki ^a   Hosoya, Yoshinori ^b   Nakajima, Takashi ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN MINT1; PROTEIN MINT2; PROTEIN MINT3; PROTEIN MLH1; PROTEIN MUTL; PROTEIN P15; PROTEIN P16; PROTEIN P73; STEM CELL FACTOR; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; MISMATCH REPAIR; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

AGED; CPG ISLANDS; DNA METHYLATION; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 38949108624     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00682.x     Document Type: Article

References (34)

1. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: A population-based study in western Sweden. Cancer 2005; 103: 821-9.
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
3. Kitamura Y, Hirota S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 2004; 61: 2924-31.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25.
5. Lasota J, Stachura J, Miettinen M. GISTS with PDGFRA exon 14 mutations represent a subset of clinically favorable gastric tumors with epithelioid morphology. Laboratory Invest 2006; 86: 94-100.
6. Fukasawa T, Chong JM, Sakurai S et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 2000; 91: 1241-9.
7. Breiner JA, Meis-Kindblom J, Kindblom LG et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet 2000; 120: 111-16.
8. Kim NG, Kim JJ, Ahn JY et al. Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer 2000; 85: 633-8.
9. Assamaki R, Sarlomo-Rikala M, Lopez-Guerrero JA et al. Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors. Genes Chromosomes Cancer 2007; 46: 564-76.
10. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH et al. Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res 2006; 66: 8984-93.
11. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
12. Kana MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
13. Salahshor S, Koelble K, Rubio C, Lindblom A. Microsatellite instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Laboratory Invest 2001; 81: 535-41.
14. Bae YK, Brown A, Garrett E et al. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 2004; 10: 5998-6005.
15. Shen L, Ahuja N, Shen Y et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002; 94: 755-61.
16. Kaneko Y, Sakurai S, Hironaka M et al. Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut 2003; 52: 641-6.
17. House MD, Guo MZ, Efron DT et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 2003; 7: 1004-14.
18. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65.
19. Sakurai S, Hasegawa T, Sakuma Y et al. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: A subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 2004; 35: 1223-30.
20. Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-12.
21. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6.
22. Ueki T, Toyota M, Sohn T et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-9.
23. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-42.
24. Kang HJ, Nam SW, Kim H et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005; 24: 1066-74.
25. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTS) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202: 430-8.
26. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
27. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77.
28. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in.vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
29. Joensuu H, Robers PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
30. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
31. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
32. Fletcher JA, Corless CL, Dimitrijevic S et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003; 22: 815S.
33. Chen LL, Trent JC, Wu EF et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-19.
34. Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-9.